<DOC>
	<DOC>NCT00961090</DOC>
	<brief_summary>A one time oral dose of ALA is taken before surgery. The medication makes the tumor visible under ultraviolet light which allow the surgeon to see more of the tumor for a more complete removal.</brief_summary>
	<brief_title>Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery</brief_title>
	<detailed_description>Patients with primary neoplastic brain tumors (Grades II-IV) will participate in this trial. Each patient will have been evaluated and found to have such a tumor by history and recent imaging studies (MRI) and deemed a surgical candidate based on current neurosurgical standards of care.</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>Suspected primary brain tumor 18 years of age or more Normal marrow and organ function Life expectancy not a consideration Receiving any other investigational agents History of allergic reactions to ALA Personal or family history of porphyrias Liver disease in the past year Uncontrolled intercurrent illness Pregnant or lactating women Inability to undergo MRI with contrast</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Brain tumor</keyword>
	<keyword>glioma</keyword>
	<keyword>surgical resection</keyword>
	<keyword>ALA</keyword>
	<keyword>ultraviolet light</keyword>
</DOC>